Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced Freezing
Authors:
- Meera E. ModiMMMeera E. Modi
- Mark J. MajchrzakMMMark J. Majchrzak
- Kari R. FonsecaKFKari R. Fonseca
- Angela DoranADAngela Doran
- Sarah OsgoodSOSarah Osgood
- Michelle Vanase-FrawleyMVMichelle Vanase-Frawley
- Eric FeyfantEFEric Feyfant
- Heather McInnesHMHeather McInnes
- Ramin DarvariRDRamin Darvari
- Derek L. BuhlDBDerek L. Buhl
- Natasha M. KablaouiNKNatasha M. Kablaoui
Open Access
- 1 August 2016
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 358 (2) , 164-172
Abstract
Oxytocin (OT) modulates the expression of social and emotional behaviors and consequently has been proposed as a pharmacologic treatment of psychiatric diseases, including autism spectrum disorders and schizophrenia; however, endogenous OT has a short half-life in plasma and poor permeability across the blood-brain barrier. Recent efforts have focused on the development of novel drug delivery methods to enhance brain penetration, but few efforts have aimed at improving its half-life. To explore the behavioral efficacy of an OT analog with enhanced plasma stability, we developed PF-06655075 (PF1), a novel non–brain-penetrant OT receptor agonist with increased selectivity for the OT receptor and significantly increased pharmacokinetic stability. PF-06478939 was generated with only increased stability to disambiguate changes to selectivity versus stability. The efficacy of these compounds in evoking behavioral effects was tested in a conditioned fear paradigm. Both central and peripheral administration of PF1 inhibited freezing in response to a conditioned fear stimulus. Peripheral administration of PF1 resulted in a sustained level of plasma concentrations for greater than 20 hours but no detectable accumulation in brain tissue, suggesting that plasma or cerebrospinal fluid exposure was sufficient to evoke behavioral effects. Behavioral efficacy of peripherally administered OT receptor agonists on conditioned fear response opens the door to potential peripheral mechanisms in other behavioral paradigms, whether they are mediated by direct peripheral activation or feed-forward responses. Compound PF1 is freely available as a tool compound to further explore the role of peripheral OT in behavioral response.Keywords
This publication has 40 references indexed in Scilit:
- Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapyTranslational Psychiatry, 2013
- Evoked Axonal Oxytocin Release in the Central Amygdala Attenuates Fear ResponseNeuron, 2012
- Oxytocin‐immunoreactive innervation of identified neurons in the rat dorsal vagal complexNeurogastroenterology & Motility, 2011
- Prosocial effects of oxytocin and clinical evidence for its therapeutic potentialFrontiers in Neuroendocrinology, 2011
- Oxytocin Reduces Background Anxiety in a Fear-Potentiated Startle Paradigm: Peripheral vs Central AdministrationNeuropsychopharmacology, 2011
- Promoting social behavior with oxytocin in high-functioning autism spectrum disordersProceedings of the National Academy of Sciences, 2010
- Measurement of cerebral blood volume in mouse brain regions using micro-computed tomographyNeuroImage, 2009
- Systemic Propranolol Acts Centrally to Reduce Conditioned Fear in Rats Without Impairing ExtinctionBiological Psychiatry, 2009
- BLOOD BINDING AND TISSUE UPTAKE OF DRUGS. RECENT ADVANCES AND PERSPECTIVESFundamental & Clinical Pharmacology, 1988
- The influence of binding to albumin and α1-acid glycoprotein on the clearance of drugs by the liverInternational Journal of Clinical Pharmacy, 1987